At ALS TDI, our mission is to find effective treatments for ALS. Often that involves trying to invent new drugs of our own, but it can also mean trying to see if treatments developed by others are promising. To do this, we perform something called “replication studies” – trying to recreate and optimize the experiments performed by other researchers to confirm that their results were accurate. This process is known as validation in the context of drug discovery.   Today on Endpoints we’re joined by ALS TDI CEO Dr. Steve Perrin, who tells us about the importance of replication and validation in the drug discovery process–and what we’re doing to test promising drug candidates that originated outside of our lab.